July 20 (Reuters) - Johnson & Johnson (NYSE:JNJ) JNJ.N :
* Health Canada approves Imbruvica (ibrutinib) for first-line treatment of chronic lymphocytic leukemia Source text for Eikon: ID:nCNW54T5ha Further company coverage: JNJ.N
(Bengaluru Newsroom: +1-646-223-8780)